FDA Clears a Redesigned Foley Catheter From Urolution Medical

FDA cleared Urolution Medical's OpenFlo Urinary Catheter on 9 October 2026, a 510(k) clearance for a device category — the indwelling, or Foley-style, urinary catheter — that has looked and worked largely the same way for decades. OpenFlo keeps the familiar silicone tube and retention balloon but splits that single balloon into two parallel, side-by-side balloons and removes the protruding distal tip that conventional catheters carry past the balloon.

Why the distal tip is the design target

A conventional Foley catheter's retention balloon sits a short distance back from the tip, leaving a length of catheter — the protruding distal segment, sometimes called the dead space or tip — extending past the balloon into the bladder. That segment and the balloon's single-point inflation are frequent focal points in the clinical and device-design literature on catheter-associated complications: encrustation, bladder irritation from the protruding tip, and injury risk when an encrusted or improperly deflated balloon is removed. Urolution's pitch for OpenFlo is that distributing retention across two parallel balloons and eliminating the protruding tip changes that geometry. The clearance itself does not validate that clinical premise; a 510(k) establishes substantial equivalence to an existing device type for safety and effectiveness purposes, which is a different and lower bar than demonstrating superior clinical outcomes.

What the clearance does and doesn't establish

FDA's 510(k) program clears devices that are substantially equivalent to a legally marketed predicate — equivalent intended use, equivalent technological characteristics or performance data showing any differences don't raise new questions of safety and effectiveness. It is the pathway nearly all indwelling urinary catheters reach market through, including the conventional Foley designs OpenFlo is meant to replace. That means OpenFlo's clearance confirms FDA found no new safety or effectiveness questions raised by the dual-balloon, tipless design relative to existing catheters — a real and necessary finding — but it does not confirm the company's comparative claims about reduced complications, which Urolution itself frames as pending clinical validation. Regulatory teams reviewing competitor clearances in this space should read “cleared” and “clinically proven to reduce complications” as two separate claims, only one of which this clearance makes.

What it means for RA/QA teams

OpenFlo is a useful reminder that 510(k) activity in long-established, high-volume device categories keeps moving even when headlines focus on novel technology. For device manufacturers and hospital procurement teams, a redesigned catheter that claims equivalent cost to the incumbent is a different adoption calculus than a premium device asking for a price increase to justify a clinical claim: the commercial case here doesn't depend on insurers or hospitals paying more, only on clinicians and purchasing committees being willing to switch a commodity product. The clinical studies Urolution says are coming next — comparing OpenFlo against conventional Foley catheters on complication rates — will be the data that actually tests whether the redesign delivers on its premise, and are worth tracking for any team benchmarking catheter-related device submissions of their own.

Frequently asked questions

What did FDA clear on 9 October 2026?

The OpenFlo Urinary Catheter, made by Urolution Medical, Inc., through the 510(k) pathway, indicated for urinary tract drainage in adult patients with indwell periods of up to 30 days.

What changed from a conventional Foley catheter?

OpenFlo replaces the single protruding balloon and distal tip of a conventional indwelling catheter with two parallel, side-by-side balloons, eliminating the protruding tip. It is manufactured using established silicone methods, at a cost the company says is comparable to conventional all-silicone Foley catheters.

What clinical evidence supports the design change?

The clearance rests on substantial equivalence to a predicate device, not a head-to-head clinical trial. Urolution says clinical studies comparing performance and outcomes are its next step; claims about reduced complications are currently the company's own, not an FDA-stated finding.

Who is Urolution Medical?

A medical device startup based in Maple Grove, Minnesota, led by co-founder and president Weihao Qu. The company has not disclosed its founding date, funding or headcount.